Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children

Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2014, Pages 201-205

  Madani, Shailender ^a   Kauffman, Ralph ^b   Simpson, Pippa ^c   Lehr, Victoria Tutag ^d   Lai, Mary Lieh ^e   Sarniak, Ashok ^f   Tolia, Vasundhara ^g  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Accreditation Council for Graduate Medical Education   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Famotidine; Gastric acid suppression; Pediatric intensive care unit; Pharmacodynamics; Pharmacokinetics; Ranitidine

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; FEMALE; GASTRIC PH MONITORING; GASTRITIS; HEAD INJURY; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK FACTOR; SCHOOL CHILD; SEPSIS; SHOCK; STOMACH ACID; STOMACH PH; STRESS; STRESS ULCER; YOUNG ADULT; BLOOD; CHEMISTRY; CRITICAL ILLNESS; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PH; SECRETION (PROCESS); SINGLE BLIND PROCEDURE;

CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; FAMOTIDINE; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTRITIS; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; INFANT; INFUSIONS, INTRAVENOUS; RANITIDINE; SINGLE-BLIND METHOD;

EID: 84895749143     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.219     Document Type: Article

References (21)

1. Deerojanawong J, Peongsujarit D, Vivatvakin B, Prapphal N. Incidence and risk factors of upper gastrointestinal bleeding in mechanically ventilated children. Pediatr Crit Care Med. 2009;10 (1):91-95. doi: 10.1097/PCC. 0b013e3181936a37
2. Reveiz L, Guerrero-Lozano R, Camacho A, Yara L, Mosquera PA. Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: a systematic review. Pediatr Crit Care Med. 2010;11(1):124-132. doi: 10.1097/PCC.0b013e3181b80e70
3. Ali T, Harty R. Stress induced ulcer bleeding in critically ill patients. Gastroenterol Clin N Am. 2009;38:245-265.
4. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm. 1999;56:347-379.
5. Cook DJ, Witt LG, Cook RJ, et al. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med. 1991;91:519-527.
6. Chin TWF, MacLeod SM, Fenje P, Baltodano A, Edmonds JF, Soldin SJ. Pharmacokinetics of cimetidine in critically-ill children. Pediatr Pharmacol. 1983;2:285-292.
7. Lugo RA, Harrison AM, Cash J, et al. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. Crit Care Med. 2001;29(4):759-764.
8. James LP, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin Pharmacokinet. 1996;31(2) 103-110.
9. Kraus G, Krishna DR, Chmelarsch D, Schmid M, Klotz U. Famotidine, pharmacokinetic properties and suppression of acid secretion in pediatric patients following cardiac surgery. Clin Pharmacokinet. 1990;18(1):77-81.
10. Wenning LA, Murphy MG, James LP, et al. Pharmacokinetics of famotidine in infants. Clin Pharmacokinet. 2005;44(4):395-406.
11. Du W, Tutag Lehr V, Caverly M, Kelm L, Lieh-Lai M. Adverse drug reactions in pediatric intensive care unit. J Clin Pharmacol. 2013;53 (5):567-573.
12. Choonara I, Rieder MJ. Drug Toxicity and Adverse Drug Reactions in Children-A Brief Historical Review. Nottingham, England: Nottingham University Press; 2004.
13. Leeder JS. Developmental pediatric pharmacogenomics. Pharmacogenomics. 2003;4(3):331-341.
14. Maples HD, James LP, Stowe CD, et al. Famotidine disposition in children with adolescents with chronic renal insufficiency. J Clin Pharmacol. 2003;43:7-14.
15. Ziemniak JA, Assael BM, Padoan R, Schentag JJ. The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patient: age-related differences as compared to adults. Eur J Clin Pharmacol. 1984;26:183-189.
16. Treem WR, Davis PM, Hyams JS. Suppression of gastric acid secretion by intravenous use of famotidine in children. J Pediatr. 1991;118(5):812-816.
17. Harrison AM, Lugo RA, Vernon DD. Gastric pH control in critically ill children receiving iv ranitidine. Crit Care Med. 1998;26:1433-1436.
18. Hawwa AF, Westwood PM, Collier PS, et al. Prophylactic ranitidine treatment in critically ill children-a population pharmacokinetic study. Br J Pharmacol. 2013;75(5):1265-1276.
19. Wincek WC. Analytical methodology for quantitation of Famotidine and H2 receptor blockers in plasma and urine. J Chromotogr. 1985;338:438-443.
20. Karnes HT, Opong-Mensah K, Farthing D, Beightol LA. Automated solid phase extraction and high performance liquid chromatographic determination of rantidine from urine, plasma and peritoneal dialysate. J Chromatogr. 1987;422:165-173.
21. Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettila V. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg. 2006;81:542-546.